News
BMS' Opdivo gets late-stage oesophageal cancer nod from FDA
The FDA has cleared two combination drug regimens based on Bristol-Myers Squibb's PD-1 inhibitor Opdivo for previously-untreated advanced oesophageal cancer, encroaching on territory held b
